An observational study in Type 1 Diabetes (T1D), Registry and Pre-diabetes, sponsored by University of Oxford. Recruiting at 1 site in United Kingdom. Open to participants aged 6 Months to 70 Years. Per ClinicalTrials.gov, last updated 2025-08-15.
Sponsored by University of Oxford · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom — 32 open to participants now, 41 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · United Kingdom.
Among the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 54 observational ones that give a count, is one of 12 that started in 2025, is one of 54 observational ones, reaches primary completion later than 24 of the 40 other live ones, and was the 255th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →32 of the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom are open now. Recruiting first, the newest first:
Sanofi · Sites in United Kingdom, Belgium, France and 3 more countries
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 17 more countries
Ages 1–35
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 16 more countries
Ages 1–35
Imperial College London · Sites in United Kingdom
Ages 18+
SAb Biotherapeutics, Inc. · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 5–40
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 6 Months to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
268 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 31 · Phase 3 53 · Phase 4 18
First in 1997; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 50 across the 214 interventional studies, 133 across the 54 observational. Of the 206 that completed or were terminated, 76 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 268 have an industry lead sponsor. The 10 most frequent:
University of Oxford is the lead sponsor of 813 studies on the registry; 119 are open to participants now.
University of Oxford has 7 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
14 of the studies in Diabetes Mellitus, Type 1 with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT06782568Imperial College LondonAvoidance of Insulin-induced Lipohypertophy in People With Diabetes Using Ultrasound Scanning Within Diabetes Clinics | 2026-12-31 |
| NCT07583238University of NottinghamDiathermy On Diabetes Glucose Monitoring Effectiveness | 2027-02 |
| NCT06815081University of OxfordCapillary OGTT Study | 2027-02-28 |
| NCT07251257University of SurreyThe Seafarers' Continuous Glucose Monitoring Systems Study | 2027-03-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Type 1 diabetes (T1D) is a life-long condition where the immune system destroys part of the body (the pancreas) which makes the chemical, insulin. Insulin is needed to control blood sugar levels. Treatment involves life-long insulin replacement by injection or insulin pump.
Previous research has shown that the development of T1D occurs through different stages. This starts with a phase where there are no symptoms, which can last months or years, before symptoms of T1D develop and a person becomes unwell. The risk of developing T1D increases with presence of markers in the blood called islet autoantibodies. The risk of developing T1D increases with presence of markers in the blood called islet autoantibodies (IAb). Children with two or more IAb have an 80-90% chance of developing T1D within 15 years. It is almost certain that they will develop the condition in their lifetime. Children with only one IAb have a much lower risk of developing T1D (around 15%). Less is understood about the natural history of being IAb positive in adults, and the investigators hope this study will help them understand more.
The aim of the research is to understand what it is like to live with being at risk of T1D, what information and support people need, and whether they use NHS services more than others, for example due to being anxious about developing T1D. The investigators will work with the public and patient involvement group using information from the research and, with the charity Diabetes UK, to create a policy statement about the type of care that is needed to support these individuals.
To be able to do this research, tbhe investigators need first to recruit these rare individuals into one single registry of children, young people and adults who have islet autoantibodies in their blood. This will also allow the invetigators to collect data from individuals in the registry to compare this to data from other countries, to help understand why people progress from being islet autoantibody positive to requiring insulin in the UK.
People entering the registry will also be told if a drug is licensed in the UK to help delay T1D onset. Participants can also consent to be contacted about any research studies, which are testing drugs or interventions to prevent or delay the start of T1D.
BACKGROUND AND RATIONALE Type 1 diabetes can be identified in the pre-clinical phase Understanding of the natural history of Type 1 diabetes (T1D) has made it possible to diagnose children, young people and adults (CYPA) in the preclinical phase. The presence of ≥ 2 Islet autoantibodies (IAb) in serum, to 4 different proteins (insulin, Glutamic Acid Decarboxylase (GADA), insulinoma-2-associated autoantibodies (IA-2A), and/or zinc transporter 8 autoantibodies (ZnT8A) identifies individuals who will develop T1D. The latency period before clinical diagnosis can last months or years, with individuals with ≥2 IAb moving between stage 1 (normoglycaemia), stage 2 (dysglycaemia) to stage 3 (hyperglycaemia), or clinical disease.
Data from combined longitudinal cohorts shows that ≥ 2 IAb in children predicts that stage 3 T1D will develop in over 80% over the next 15 years, and near 100% over a lifetime, whereas only around 10-15% children with a single IAb progress to insulin requirement. Individuals may therefore live for many years with the knowledge they may develop T1D .
Potential benefits of early identification of T1D Identifying T1D before symptoms develop has several potential advantages, including reducing presentation with life-threatening diabetic ketoacidosis (DKA) and its associated morbidity, and potentially reducing the psychological trauma at diagnosis which some families liken to 'post-traumatic distress' . Reducing DKA and hospitalisations can also reduce associated health care costs. Screening identifies individuals suitable for trials to prevent or delay T1D. Therapies are now being trialled in stage 2 T1D, for example, the ATG prevention trial 'STOP-T1D'.
Concerns about screening Informing someone that they have positive IAb may cause psychological stress. For example, the Fr1da study, which has now tested > 170,000 children for IAb, found that informing parents of their child's positive IAb result induced stress (assessed by the Patient Health Questionnaire-9); this stress declined after 12 months of follow up. Within the registry, the investigators have recourse to the advice of a senior clinical psychologist, who can provide signposting support for individuals identified through the registry, if psychological concerns arise.
Screening initiatives Until recently, screening strategies have focussed on first-degree relatives (FDR) of individuals with T1D, who have a 15 times higher risk of developing stage 3 T1D compared to the general population. However, since > 85% of people with T1D do not have a family history, general population screening efforts have been started.
There are now several different screening programs in the UK identifying children, young people and adults with IAbs. It is anticipated that there are approximately 700 such children and adults from the different research platforms. These individuals do not typically present to their general practitioner as they have no symptoms, and therefore it is extremely rare to know of such individuals in the UK. Individuals can also be identified from clinical care (personal communication Besser \& Randell, BSPED). In order to answer our research questions, the investigators need a mechanism to identify, recruit and consent such individuals into a single combined registry.
Potential participants will be identified via:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children and adults aged 6 months - 70 years, positive for ≥ 1 islet autoantibody (IAb)
Number of individuals enrolled on the registry
Time frame: 36 months
Participants' perspectives and experiences
Interviews, to to understand the lived experience of being IAb positive or having a child who is IAb positive.
Time frame: 28 months
Participants' perspectives and experiences
Interviews, to understand people's information and support needs when living with an IAb result, to improve the information and support given to people and their families who receive a positive T1D IAb result in the future and create a position statement informed by our findings.
Time frame: 28 months
Frequency and risk factors (e.g. antibody profile, age) associated with clinical outcomes incident diabetes as defined by start of insulin use and number of DKA episodes
We will undertake data linkage with routinely collected NHS clinical datasets held by NHSE (and the equivalent for the devolved nations)
Time frame: 28 months
Frequency and risk factors (e.g. antibody profile, age) associated with HbA1c mmol/l
To undertake data linkage with routinely collected NHS clinical datasets held by NHSE (and the equivalent for the devolved nations)
Time frame: 28 months
Frequency of attendance in primary care
To assess the status of being IAb positive on health service usage and clinical outcomes using comparator cohorts (e.g. CPRD/HES)
Time frame: 36 months
Frequency of attendance and inpatient admission to secondary/ tertiary care
To assess the status of being IAb positive on health service usage and clinical outcomes using comparator cohorts (e.g. CPRD/HES)
Time frame: 36 months
IAb type (IA, IA-2, ZnT8, GAD, ICA)
To compare IAb characteristics to similar cohorts from international registries
Time frame: 36 months
IAb laboratory (location)
To compare IAb characteristics to similar cohorts from international registries
Time frame: 36 months
IAb titre (mULN)
To compare IAb characteristics to similar cohorts from international registries
Time frame: 36 months
Demographic data
To compare demographic characteristics to similar cohorts from international registries
Time frame: 36 months
Time to clinical diagnosis (defined as stage 3 T1D) according to standard diagnostic criteria
To assess risk of progression to stage 3 T1D in IAb positive individuals in the UK
Time frame: 36 months
Number of individuals who have consented and enrolled to the registry
To assess consent to the registry vs enrolment
Time frame: 36 months
IAb number (1-4)
To compare the proportion identified as confirmed positive from clinical care vs reference laboratories
Time frame: 36 months
IAb type (IA-2, IA, ZnT8, GAD, ICA)
To compare the proportion identified as confirmed positive from clinical care vs reference laboratories
Time frame: 36 months
IAb titre (mULM)
To compare the proportion identified as confirmed positive from clinical care vs reference laboratories
Time frame: 36 months
Plan to share: Yes — All IPD will be considered for data sharing.
Supporting information: Study protocol, Informed consent form
Time frame: Access to data will not be considered until after the primary publication for the registry has been published
Access criteria: Subject to participant consent, data will be shared with other researchers for research projects that have appropriate ethical approval. Requests for access to the data will be controlled by the Data Access Committee.
Started Jul 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.
Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 22 months is below that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.